Skip to main content
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE Design, rationale, and clinical implications THROMBOSIS AND HAEMOSTASIS Raskob, G. E., Spyropoulos, A. C., Zrubek, J., Ageno, W., Albers, G., Elliott, C. G., Halperin, J., Haskell, L., Hiatt, W. R., Maynard, G. A., Peters, G., Spiro, T., Steg, P. G., Suh, E. Y., Weitz, J. I. 2016; 115 (6): 1240-1248


Hospital-associated venous thromboembolism (VTE) is a leading cause of premature death and disability worldwide. Evidence-based guidelines recommend that anticoagulant thromboprophylaxis be given to hospitalised medical patients at risk of VTE, but suggest against routine use of thromboprophylaxis beyond the hospital stay. The MARINER study is a randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of thromboprophylaxis using rivaroxaban, begun at hospital discharge and continued for 45 days, for preventing symptomatic VTE in high-risk medical patients. Eligible patients are identified using the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE VTE) risk score, combined with a laboratory test, D-dimer. The rivaroxaban regimen is 10 mg once daily for patients with CrCl =?50 ml/min, or 7.5 mg once daily for patients with CrCl =?30 ml/min and

View details for DOI 10.1160/TH15-09-0756

View details for Web of Science ID 000377237400020

View details for PubMedID 26842902